Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
about
Molecular prognostic factors in cytogenetically normal acute myeloid leukemiaProgress in acute myeloid leukemiaPrognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerEmerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.Molecular diagnostics in acute leukemias.Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.The role of therapeutic leukapheresis in hyperleukocytotic AML.p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AMLPrognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis.Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsClinical implications of FLT3 mutations in pediatric AML.FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Current therapeutic strategies for acute myeloid leukaemia.Prognostic impact and targeting of CRM1 in acute myeloid leukemia.Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemiaEradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Interactive diagnostics in the indication to allogeneic SCT in AML.MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cellsInvestigational drugs targeting FLT3 for leukemia.Lestaurtinib: a multi-targeted FLT3 inhibitor.FMS-like tyrosine kinase 3 inhibitors: a patent review.Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Molecular markers in acute myeloid leukaemia.Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.Do anti-angiogenic cancer therapies increase risk of significant weight loss?Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
P2860
Q26998811-E41109E8-B3B0-40DB-BF28-2749FC6784B6Q27024006-70C729FF-3B41-4E8F-8846-85B32F615137Q27853004-6FE8B465-2CB5-41C4-91B0-15D608A5AB78Q28538435-6A01A575-947A-4225-8AC6-4F8163DF9322Q34004131-F92CC695-9E79-42D7-89F1-88F1201D873FQ34011740-FCEA62CF-64A2-475F-B40B-7121509CC10AQ34097586-7768212F-2E9F-4B9A-A5C6-6E757234A898Q34176732-2194C468-6427-4C8A-977B-420905D48A02Q34976428-CC1F437D-66F7-4F60-9741-2AEF939FA93DQ35007333-20752DAC-3998-4EAC-875E-5CEC09B7EF2EQ35067345-0AA7F341-31F0-4586-8E42-D35FB36E9EC6Q35114397-E5B3056C-8CE8-4914-8E08-716A2CB4EA3CQ35148107-0A9538E5-ECC8-4E8C-9413-DD6CECCCCD4EQ35485832-4F853BE1-97AB-4D6D-AE02-1C6D35D84734Q35584427-62E1C97A-240E-4598-8C8E-11CFBF069481Q35739494-D0BDBB46-E425-4086-90D4-DCB6F7071337Q35777301-B0ED1475-9EAC-42D4-A2F0-A6661A408662Q35848830-45A3BE18-F238-4F07-947B-7C39F3458A27Q35848876-123C3451-1645-4BBB-8897-5AC66BF76888Q35849209-53D85BC7-197E-4C32-8B84-5D7BECEFD519Q35920569-6163754E-3009-4048-BF3E-897394B37326Q36390379-5F5A43DF-224B-4138-BAFC-4067E7CFD4BFQ36461618-5D757247-94B0-42F0-8D2B-DB6D880F4E57Q36539598-9DF022B7-2E22-482D-88C0-B1742339130EQ36850849-2D263DAB-2994-4050-A072-98BCE45BB5A5Q36925156-7FE464BA-15E1-4F5B-B535-3A0A4B23C981Q37349410-BF551F84-5A96-486F-B114-FA63F281AC7DQ37442649-EED9E6BA-4C18-4A58-A6CA-20C4883995BBQ37535249-17AC0EA9-0563-4845-9884-70236A1228D5Q37577934-CDDCAA13-4BB2-4E5B-A672-4EAA6357A96FQ37810104-52C81A18-770F-4A66-AF72-D64E9BFC64C4Q37842585-383A0D0A-0BE7-4D70-B274-8EF905758068Q37842861-64D98C49-F3FE-418F-9A1B-93D1A938834CQ37954583-BBD4198E-F706-4B2B-B000-C35FFBE585FFQ38026007-C25C90E3-4D28-4B9F-86C2-2D71162CEFEAQ38168893-B0BF1556-6940-4061-AF50-B56D78C7EFDDQ38192670-98F8F620-FE2A-4DF1-BD3A-0DB842EFC96DQ38207607-4B749EEA-49C2-4A36-B8E4-6474E5FF7168Q38213704-5AF37074-F338-4CB5-8FD9-01EDB3B8C627Q38694866-FE512565-BA65-46F0-8A62-5E8281AE46BB
P2860
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@en
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@nl
type
label
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@en
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@nl
prefLabel
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@en
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@nl
P2093
P2860
P356
P1433
P1476
Prognostic significance of FLT ...... oid leukemia: a meta-analysis.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403838
P577
2005-08-01T00:00:00Z